Dr. Lena-Sophie Schütter
Investment Manager
About me
| Team | Life Sciences & Chemistry |
| at HTGF since | 2024 |
CV
Dr. Lena Schütter is an Investment Manager in the Life Science Team at HTGF in Bonn. Prior to this, she worked for several years in various sales positions at QIAGEN GmbH. She completed her studies in molecular biology in Göttingen. During her studies, she completed numerous internships in Germany and abroad. Lena Schütter then completed her doctorate in genetics at the renowned ageing research institute CECAD in Cologne. In addition to her doctorate, Lena Schütter studied business administration at the University of Hagen.
My success stories in the HTGF portfolio
inContAlert was founded in September 2022 within the ecosystem of the University of Bayreuth. The MedTech startup’s sensor system empowers patients with neurogenic bladder dysfunction to manage their bladder on …
To the complete profileof inContAlert
Altavo is a Dresden based medical technology startup founded in February 2021. Based on non-invasive radar sensing and AI algorithms for speech recognition and synthesis, Altavo is developing prosthetics to …
To the complete profileof Altavo
NAVAN, Inc. (NAVAN) is an early-stage private biotechnology company developing a novel, proprietary NanoStraw platform to enable the next generation of cell and gene therapies. A non-viral physical delivery technology, …
To the complete profileof Navan
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in …
To the complete profileof Signatope
Guided to exit
Exit
GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with …
To the complete profileof GQ Bio Therapeutics
Social Media & contact
LinkedIn
Dr. Lena-Sophie Schütter
Profil